Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BCLI $14 Price Target today
Current Price $3.97
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_12132021_BCLI_Bautz.pdf
$BCLI is shorted every day.
$ABUS Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
Arbutus to receive $40 million in an upfront payment, up to $245 million in development and commercialization milestone payments, double-digit tiered royalties and a $15 million equity investment
https://finance.yahoo.com/news/arbutus-qilu-pharmaceutical-enter-exclusive-123000244.html
Arbutus Shares Rise Moderna's Fall After Patent Appeal Denied
https://finance.yahoo.com/news/arbutus-shares-rise-modernas-fall-122220873.html
$ABUS Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
Arbutus to receive $40 million in an upfront payment, up to $245 million in development and commercialization milestone payments, double-digit tiered royalties and a $15 million equity investment
https://finance.yahoo.com/news/arbutus-qilu-pharmaceutical-enter-exclusive-123000244.html
Arbutus Shares Rise Moderna's Fall After Patent Appeal Denied
https://finance.yahoo.com/news/arbutus-shares-rise-modernas-fall-122220873.html
$BCLI BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
https://finance.yahoo.com/news/brainstorm-cell-therapeutics-announces-peer-120000423.html
$BCLI BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
https://finance.yahoo.com/news/brainstorm-cell-therapeutics-announces-peer-120000423.html
ACT for ALS Passes House while BrainStorm Prepares Moves Ahead with NurOwn
https://www.biospace.com/article/milestone-act-for-als-bill-gets-unanimous-vote-from-congress-senate-next/
SENATE LIST (Updated Dec. 10th) 58 Total sponsors
Do you have a link?. Thanks.
$DWAC $59
$DWACW $18
DWACW Exercise price $11.50
DWACW should be trading much higher
$DWAC $59
$DWACW $18
DWACW Exercise price $11.50
DWACW should be trading much higher
$DWAC $59
$DWACW $18
DWACW Exercise price $11.50
DWACW should be trading much higher
$BCLI Senate List 51 sponsors for S.1813 - Accelerating Access to Critical Therapies for ALS Act
500 Million
"For purposes of carrying out this Act, there are authorized to be appropriated $100,000,000 for each of fiscal years 2022 through 2026. "
$BCLI NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show
https://alsnewstoday.com/news-posts/2021/12/02/nurown-meaningful-benefit-slower-als-progression-earlier-stage-patients-phase-3-trial-analyses
$BCLI Senate List 51 sponsors for S.1813 - Accelerating Access to Critical Therapies for ALS Act
500 Million
"For purposes of carrying out this Act, there are authorized to be appropriated $100,000,000 for each of fiscal years 2022 through 2026. "
$BCLI NurOwn of ‘Meaningful’ Benefit to Earlier Stage Patients, Data Show
https://alsnewstoday.com/news-posts/2021/12/02/nurown-meaningful-benefit-slower-als-progression-earlier-stage-patients-phase-3-trial-analyses
$CEMI COVID-19 related
Float 28.3 M
Short Interest 11.03 ~ 14.66
2 years high $15.89
News: Chembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen Test
https://finance.yahoo.com/news/chembio-diagnostics-receives-sahpra-approval-130000218.html
News: Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test
$CEMI COVID-19 related
Float 28.3 M
Short Interest 11.03 ~ 14.66
2 years high $15.89
News: Chembio Diagnostics Receives SAHPRA Approval for DPP SARS-CoV-2 Antigen Test
https://finance.yahoo.com/news/chembio-diagnostics-receives-sahpra-approval-130000218.html
News: Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test
$BCLI Important Notes
From Q1 2021 Earnings Call Transcript
Chaim Lebovits: Given the important changes, we are in active dialogue with regulators around our regulatory plan and we will share this as soon as appropriate.
Chaim Lebovits: We cannot get talked to the EAP results. Very warming to hear what you're saying, you're describing. And I do hope that we should be able to share with you some good news very soon.
David Setboun: We are actively engaging with a variety of potential partners, which include mid-sized and leading pharmaceutical companies.
Chaim Lebovits: Looking forward for a very exciting quarter.
Add to that
Senate List 48 sponsors for S.1813 - Accelerating Access to Critical Therapies for ALS Act.
500 Million
"For purposes of carrying out this Act, there are au theorized to be appropriated $100,000,000 for each of fiscal years 2022 through 2026. "
BCLI: Biomarkers Predict Response in ALS Phase 3 Trial
https://www.yahoo.com/now/bcli-biomarkers-predict-response-als-102400354.html
Zacks Small-Cap Research Sets $11 Valuation
Maybe Positive Peer Review
Please add to the list, if you have any...
$BCLI Important Notes
From Q1 2021 Earnings Call Transcript
Chaim Lebovits: Given the important changes, we are in active dialogue with regulators around our regulatory plan and we will share this as soon as appropriate.
Chaim Lebovits: We cannot get talked to the EAP results. Very warming to hear what you're saying, you're describing. And I do hope that we should be able to share with you some good news very soon.
David Setboun: We are actively engaging with a variety of potential partners, which include mid-sized and leading pharmaceutical companies.
Chaim Lebovits: Looking forward for a very exciting quarter.
Add to that
Senate List 48 sponsors for S.1813 - Accelerating Access to Critical Therapies for ALS Act.
500 Million
"For purposes of carrying out this Act, there are au theorized to be appropriated $100,000,000 for each of fiscal years 2022 through 2026. "
BCLI: Biomarkers Predict Response in ALS Phase 3 Trial
https://www.yahoo.com/now/bcli-biomarkers-predict-response-als-102400354.html
Zacks Small-Cap Research Sets $11 Valuation
Maybe Positive Peer Review
Please add to the list, if you have any...
$BCLI Results from Phase 3 ALS Trial to be Published in Peer Reviewed Journal
$BCLI Results from Phase 3 ALS Trial to be Published in Peer Reviewed Journal #ALS #Neurology - https://t.co/8MhQv1JD4n pic.twitter.com/oyo5b0Z7pF
— Zacks SCR (@ZacksSmallCap) November 24, 2021
News today on TOS
BCLI: Biomarkers Predict Response in ALS Phase 3 Trial
https://finance.yahoo.com/news/bcli-biomarkers-predict-response-als-102400354.html
$HVCW 0005 / 0006 Pink Limited Information
Pink Current soon
Attorney Letter 11/16/2021
Verified Profile 11/2021
Transfer Agent Verified
https://www.otcmarkets.com/stock/HVCW/profile
Debt mature in 2022
Authorized Shares 5,000,000,000
Outstanding Shares 4,798,634,324
18 Million Income, Annual Report 06/30/2021
Total Revenue
6/30/2020 3,330M
6/30/2019 4,258M
https://www.otcmarkets.com/stock/HVCW/financials
$HVCW was above 0031 6 times since Jan this year
Active Twitter account
https://twitter.com/HVWINC1
Latest tweet 11/16/2021
$HVCW. Attorney letter posted. Should be Pink Current soon."
$HVCW 18 Million Income, Annual Report 06/30/2021
https://www.otcmarkets.com/otcapi/company/financial-report/306614/content
Page 13 of 33
$HVCW 18 Million Income, Annual Report 06/30/2021
https://www.otcmarkets.com/otcapi/company/financial-report/306614/content
Page 13 of 33
and here is the link to prove it
https://www.otcmarkets.com/otcapi/company/financial-report/306614/content
Page 13 of 33
$HVCW 0005 / 0006 Pink Limited Information
Pink Current soon
Attorney Letter 11/16/2021
Verified Profile 07/2021
Transfer Agent Verified
https://www.otcmarkets.com/stock/HVCW/profile
Debt mature in 2022
Authorized Shares 5,000,000,000
Outstanding Shares 4,798,634,324
18 Million Income, Annual Report 06/30/2021
Total Revenue
6/30/2020 3,330M
6/30/2019 4,258M
https://www.otcmarkets.com/stock/HVCW/financials
$HVCW was above 0031 6 times since Jan this year
Active Twitter account
https://twitter.com/HVWINC1
Latest tweet 11/16/2021
$HVCW. Attorney letter posted. Should be Pink Current soon."
$HVCW 0005 / 0006 Pink Limited Information
Pink Current soon
Attorney Letter 11/16/2021
Verified Profile 07/2021
Transfer Agent Verified
https://www.otcmarkets.com/stock/HVCW/profile
Debt mature in 2022
Authorized Shares 5,000,000,000
Outstanding Shares 4,798,634,324
18 Million Income, Annual Report 06/30/2021
Total Revenue
6/30/2020 3,330M
6/30/2019 4,258M
https://www.otcmarkets.com/stock/HVCW/financials
$HVCW was above 0031 6 times since Jan this year
Active Twitter account
https://twitter.com/HVWINC1
Latest tweet 11/16/2021
$HVCW. Attorney letter posted. Should be Pink Current soon."
$HVCW 0005 / 0006 Pink Limited Information
Pink Current soon
Attorney Letter 11/16/2021
Verified Profile 07/2021
Transfer Agent Verified
https://www.otcmarkets.com/stock/HVCW/profile
No Dilution, debt mature in 2022
Authorized Shares 5,000,000,000
Outstanding Shares 4,798,634,324
18 Million Income, Annual Report 06/30/2021
Total Revenue
6/30/2020 3,330M
6/30/2019 4,258M
https://www.otcmarkets.com/stock/HVCW/financials
$HVCW was above 0031 6 times since Jan this year
Active Twitter account
https://twitter.com/HVWINC1
Latest tweet 11/16/2021
"$HVCW. Attorney letter posted. Should be Pink Current soon."
$HVCW 0005 / 0006 Pink Limited Information
Pink Current soon
Attorney Letter 11/16/2021
Verified Profile 07/2021
Transfer Agent Verified
https://www.otcmarkets.com/stock/HVCW/profile
No Dilution, debt mature in 2022
Authorized Shares 5,000,000,000
Outstanding Shares 4,798,634,324
18 Million Income, Annual Report 06/30/2021
Total Revenue
6/30/2020 3,330M
6/30/2019 4,258M
https://www.otcmarkets.com/stock/HVCW/financials
$HVCW was above 0031 6 times since Jan this year
Active Twitter account
https://twitter.com/HVWINC1
Latest tweet 11/16/2021
"$HVCW. Attorney letter posted. Should be Pink Current soon."
$BCLI Senate List 45 sponsors for S.1813 - Accelerating Access to Critical Therapies for ALS Act
$BCLI: ALS bill would provide $100m annually to access potential drugs
https://endpts.com/fda-roundup-als-bill-would-provide-100m-annually-to-access-potential-drugs-fda-needs-to-better-enforce-clinicaltrials-gov-reporting-researchers-say/
$BCLI from Q1 2021 Earnings Call Transcript
Chaim Lebovits: We cannot get talked to the EAP results. Very warming to hear what you're saying, you're describing. And I do hope that we should be able to share with you some good news very soon.
David Setboun: We are actively engaging with a variety of potential partners, which include mid-sized and leading pharmaceutical companies.
Chaim Lebovits: Looking forward for a very exciting quarter.
$BCLI BCLI: Biomarkers Predict Response In ALS Phase 3 Trial
Valuation $11
https://scr.zacks.com/news/news-details/2021/BCLI-Biomarkers-Predict-Response-in-ALS-Phase-3-Trial-article/default.aspx
$BCLI BCLI: Biomarkers Predict Response In ALS Phase 3 Trial
Valuation $11
https://scr.zacks.com/news/news-details/2021/BCLI-Biomarkers-Predict-Response-in-ALS-Phase-3-Trial-article/default.aspx
$BCLI Watching Brainstorm Cell Therapeutics; Zacks Small-Cap Research Sets $11 Valuation
https://www.benzinga.com/analyst-ratings/price-target/21/11/24148454/watching-brainstorm-cell-therapeutics-zacks-small-cap-research-sets-11-valuation
$BCLI Watching Brainstorm Cell Therapeutics; Zacks Small-Cap Research Sets $11 Valuation
https://www.benzinga.com/analyst-ratings/price-target/21/11/24148454/watching-brainstorm-cell-therapeutics-zacks-small-cap-research-sets-11-valuation
$CRTD Volume +9.7M
Float 11.77M
News today: Dune Glow Remedy, a Creatd Ventures brand, Featured on Access Hollywood
https://finance.yahoo.com/news/dune-glow-remedy-creatd-ventures-200000320.html
$CRTD Volume +9.7M
Float 11.77M
News today: Dune Glow Remedy, a Creatd Ventures brand, Featured on Access Hollywood
https://finance.yahoo.com/news/dune-glow-remedy-creatd-ventures-200000320.html